- Home
- FRD vs PLX Comparison
FRD vs PLX Comparison
Compare FRD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | PLX |
|---|---|---|
| Founded | 1965 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 159.5M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FRD | PLX |
|---|---|---|
| Price | $20.64 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 22.4K | ★ 817.2K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | 0.22 |
| Revenue | ★ $121,157,278.00 | $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.02 | ★ $9.32 |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.52 | $1.34 |
| 52 Week High | $24.37 | $3.19 |
Technical Indicators
Market Signals| Indicator | FRD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 52.20 |
| Support Level | $20.54 | $2.06 |
| Resistance Level | $22.76 | $2.16 |
| Average True Range (ATR) | 1.01 | 0.13 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 33.39 | 76.03 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.